Pregnancy Medication Market size to exceed USD 112 billion by 2032

Pregnancy Medication Market size is poised to surpass USD 112 billion by 2032, according to a new research report by Global Market Insights Inc.
 

Increased awareness about the benefits of dietary supplements in pregnancy and healthy childbirth is a crucial factor positively influencing the industry landscape. Gynecologists globally recommend consuming dietary supplements such as iron, calcium, folic acid, vitamins, minerals, and other micronutrients to support maternal health and improve birth outcomes.
 

Health conditions such as folate deficiency, anemia, etc., caused due to improper nutrition have become quite predominant in expecting mothers and lead to severe health consequences such as neural tube defects (NTDs). These intricacies, coupled with the increasing focus on ensuring mother and fetal health, may drive the industry revenues.
 

Growing incidences of acidity and heartburn to increase the share of antacids

Pregnancy medication market from antacids segment is projected to witness more than 11% CAGR from 2023 to 2032. The escalating hormonal changes and growing baby pressing against the stomach can lead to conditions such as heartburn, acid reflux, or indigestion. Antacids help neutralize the acid in the stomach and do not cause any harm to the unborn. The increased severity of vomiting and nausea during the pregnancy and the easy over-the-counter availability of these medications will bolster the segment progression.
 

Browse key industry insights spread across 255 pages with 247 market data tables & 14 figures & charts from the report, “Pregnancy Medication Market Size By Drug Class (Antianemia, Antacids, Antiallergic, Analgesics, Antimicrobials, Hormones, Laxatives, Vaccines, Nutritional Supplements {Minerals, Omega 3, Folic Acid, Vitamins, Multivitamins}), By Pregnancy Stage (1st Trimester, 2nd Trimester, 3rd Trimester), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2023 – 2032” in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/pregnancy-medication-market
 

Increasing emphasis on healthy fetal development to foster product adoption

Pregnancy medication market from the 1st-trimester segment was worth over USD 9.5 billion in 2022. Nutritional supplements, such as iron, iodine, and folate, are prescribed by gynecologists during the first three months of the pregnancy to ensure good nutrition and development of the fetus. These nutrients help prevent low birth weight and neural tube defects in the unborn. The prevalence of anemia in expecting mothers will foster the adoption of pregnancy medications in 1st trimester.
 

Effective patient care & treatment to aid the growth of the hospital pharmacies

Hospital pharmacy segment held over 54.5% business share in 2022 and is poised to record a noticeable valuation by 2032. The easy accessibility to medical staff and healthcare professionals across hospital premises helps establish better interaction with the patient, thus ensuring favorable outcomes. The wide range availability of specialized medications and experimentation drugs to support optimal patient care and treatment will help hospital pharmacies grow as a prominent revenue pocket.
 

Robust competitive landscape to streamline industry growth across the Asia pacific

Asia Pacific pregnancy medication market is predicted to reach USD 37 billion by 2032. Asia Pacific has the presence of major industry participants focused on introducing cutting-edge products. The increasing incidences of pregnancy and birth-related complexities in the region and the availability of robust healthcare infrastructure will support the expansion of the regional industry.
 

Strategic alliances to stimulate the competitive outlook

Prominent players in the pregnancy medication industry are Alkem Laboratories Limited, Piramal Enterprises Limited, F.Hoffman-La Roche Ltd, Pfizer, Dr. Reddy’s Laboratories, Cipla Inc, Alembic Pharmaceuticals Ltd, Lupin Limited, Glenmark Pharmaceuticals Ltd, Viatris Inc.,  (Mylan Inc.), and Amgen Inc. These companies have been focusing on strengthening their strategic alliances to safeguard their position in the market.